DRUG
Bright Minds Biosciences Inc.
There isn't enough reported data to score DRUG yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
DRUG Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
DRUG's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
DRUG PE Valuation
DRUG has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
DRUG Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| -- | |
| -- | |
| Limited | |
| Low |
Analysts expect DRUG's losses to grow, with revenue holding steady. However, they disagree widely on these estimates.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
DRUG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.94 | -$0.86 |
| Q1 2026 | -$2.28 | -$1.76 |
| Q4 2025 | -$1.93 | -$1.76 |
| Q3 2025 | -$1.24 | -$0.75 |
| Q2 2025 | -$1.08 | -$0.42 |
| Q1 2025 | -$0.52 | +$0.44 |
| Q4 2024 | -$0.17 | +$1.10 |
| Q3 2024 | -$0.49 | +$0.94 |
DRUG is still losing money, but far less than before: $1.94 per share over the past year, against $4.72 at its worst in early 2022.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over DRUG on earnings, with more consistent year-over-year improvement.
DRUG Quarterly Revenue
DRUG's revenue is shrinking: $0 last quarter.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over DRUG on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
DRUG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$5.9M | -$3.5M |
| Q1 2026 | -$6.7M | -$5M |
| Q4 2025 | -$4.1M | -$3M |
| Q3 2025 | -$891.5K | -$565.8K |
| Q2 2025 | -$2.5M | -1559% |
| Q1 2025 | -$1.7M | -$1.1M |
| Q4 2024 | -$1.1M | -$472.7K |
| Q3 2024 | -$325.6K | +$516.3K |
DRUG has burned cash in almost every quarter: −$18M over the past year, against −$6M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over DRUG on cash generation, producing positive trailing cash flow while its opponent burns cash.
DRUG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.5% | +241K shares |
| 1 year | +39% | +2.7M shares |
| 3 years | +161% | +6.1M shares |
| 5 years | +334% | +7.6M shares |
| Available history | +749% | +8.7M shares |
DRUG has 10M diluted shares, up 39% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
DRUG hasn't bought back shares in the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over DRUG on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
DRUG Net Leverage
DRUG's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
DRUG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.4 | Oversold |
| Stochastic | 11.7 | Oversold |
DRUG's weekly RSI is 24 (oversold) and its Stochastic is 12 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
DRUG PE vs Healthcare Sector
DRUG has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
DRUG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $45.1 | 50% below |
| 20 week MA | $61.1 | 63% below |
| 50 week MA | $72.0 | 68% below |
| 100 week MA | $56.0 | 59% below |
| 200 week MA | $30.8 | 26% below |
DRUG is in a downtrend: it's below all five of its weekly moving averages, and 26% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
DRUG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $26.8 | $17.0 | -36% |
| 2022 | $17.0 | $4.11 | -76% |
| 2023 | $4.11 | $1.43 | -65% |
| 2024 | $1.43 | $39.9 | +2689% |
| 2025 | $39.9 | $82.1 | +106% |
| 2026 YTD | $82.1 | $22.7 | -72% |
DRUG's yearly returns have swung widely, from +2689% in 2024 to −76% in 2022. It's down 72% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over DRUG on returns for 2026, with the stronger performance.